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A B S T R A C T
The nuclear receptor liver X receptor (LXR) impacts on cholesterol metabolism as well as hepatic lipogenesis via
transcriptional regulation. It is proposed that inhibition of the protein arginine methyltransferase 3 (PRMT3)
uncouples these two transcriptional pathways in vivo by acting as a specific lipogenic coactivator of LXR. Here
we validated the hypothesis that treatment with the allosteric PRMT3 inhibitor SGC707 will diminish the hepatic
steatosis extent, while leaving global cholesterol metabolism, important in cholesterol-driven pathologies like
atherosclerosis, untouched. For this purpose, 12-week old hyperlipidemic apolipoprotein E knockout mice were
fed a Western-type diet for six weeks to induce both hepatic steatosis and atherosclerosis. The mice received 3
intraperitoneal injections with SGC707 or solvent control per week. Mice chronically treated with SGC707
developed less severe hepatic steatosis as exemplified by the 51% reduced (P < 0.05) liver triglyceride levels. In
contrast, the extent of in vivo macrophage foam cell formation and aortic root atherosclerosis was not affected
by SGC707 treatment. Interestingly, SGC707-treated mice gained 94% less body weight (P < 0.05), which was
paralleled by changes in white adipose tissue morphology, i.e. reduction in adipocyte size and browning.
In conclusion, we have shown that through PRMT3 inhibitor treatment specific functions of LXR involved in
respectively the development of fatty liver disease and atherosclerosis can be uncoupled, resulting in an overall
diminished hepatic steatosis extent without a negative impact on atherosclerosis susceptibility. As such, our
studies highlight that PRMT3 inhibition may constitute a novel therapeutic approach to limit the development of
fatty liver disease in humans.
1. Introduction
Hepatic steatosis is a condition where neutral lipids in the liver
accumulate [1]. Hepatic steatosis and related disorders are the most
common form of liver disease [2]. The prevalence is rapidly growing as
a result of the rising numbers of people with obesity and diabetes [3].
Augmented de novo hepatic lipogenesis, a process regulated by the
nuclear receptor liver X receptor (LXR) is associated with an increased
risk for hepatic steatosis [4]. The nuclear receptor stimulates the
transcription of genes essential for de novo hepatic triglyceride synth-
esis: acetyl-CoA carboxylase (ACC1), fatty acid synthase (FAS), and
stearoyl-coenzyme A desaturase 1 (SCD1) [5]. In addition, LXR is es-
sential in hepatic and macrophage cholesterol metabolism [6]. Upon
activation by its oxysterol ligands, LXR transcriptionally activates he-
patic genes involved in the conversion of cholesterol to bile acid and the
direct secretion of cholesterol into the bile, i.e. cholesterol 7α-hydro-
xylase, ATP-binding cassette (ABC) transporters G5 (ABCG5) and G8
(ABCG8). In macrophages, LXR stimulates the efflux of cellular cho-
lesterol via ABCA1 and ABCG1 [7]. Thus, in contrast to LXR's harmful
role in hepatic steatosis, LXR protects against atherosclerosis by de-
creasing the accumulation of cholesterol in macrophages and pre-
venting foam cell formation [8]. Protein arginine N-methyltransferase 3
(PRMT3) acts as a specific cofactor for LXR transcription [9]. Studies by
Kim et al. have shown that inhibition of PRMT3 function protects
against hepatocyte triglyceride accumulation in vitro [9]. We have
confirmed a potential role for PRMT3 in the development of hepatic
https://doi.org/10.1016/j.bbadis.2019.02.012
Received 9 August 2018; Received in revised form 7 February 2019; Accepted 12 February 2019
Abbreviations: ABC transporter, ATP-binding cassette transporter; ACC1, acetyl-CoA carboxylase 1; ADMA, asymmetric dimethylarginine; ALT, alanine amino-
transferase; ApoE, apolipoprotein E; cCIMT, common Carotid Intima-Media Thickness; FAS, fatty acid synthase; LPL, lipoprotein lipase; LXR, liver X receptor; MCP1,
monocyte chemoattractant protein 1; oxLDL, oxidized LDL; PRMT3, protein arginine methyltransferase 3; SDMA, symmetric dimethylarginine; SREBP-1c, sterol
regulatory element-binding protein-1c; SCD1, stearoyl-coenzyme A desaturase 1; TNFα, tumor necrosis factor alpha; UCP1, uncoupling protein 1
⁎ Corresponding author.
E-mail address: hoekstra@lacdr.leidenuniv.nl (M. Hoekstra).
BBA - Molecular Basis of Disease 1865 (2019) 1402–1409
Available online 15 February 2019
0925-4439/ © 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license 
(http://creativecommons.org/licenses/BY-NC-ND/4.0/).
T
steatosis in a short-term in vivo setting [10]. More specifically, mice
treated with the selective PRMT3 antagonist SGC707 were protected
from fatty liver development induced by LXR activation using
T0901317 and palm oil [11]. Importantly, we noticed that the antici-
pated reduction in LXR activity upon SGC707 treatment was selective
for the hepatic lipogenesis genes, as the LXR-driven genes involved in
cholesterol metabolism were not affected by pharmacological blockade
of PRMT3 activity. Uncoupling of the two LXR activities is interesting in
light of potential therapeutic use of the SGC707 compound. Treatment
with SGC707 could theoretically diminish hepatic steatosis, while
leaving hepatic and macrophage cholesterol metabolism, important in
cholesterol-driven pathologies like atherosclerosis, untouched. To va-
lidate this hypothesis, the effect of chronic PRMT3 inhibition through
SGC707 treatment was investigated in atherosclerosis-susceptible hy-
perlipidemic apolipoprotein E (apoE) knockout mice.
2. Materials and methods
2.1. Mice
Animal experiments were approved by the Ethics Committee for
Animal Experiments of Leiden University and performed at the
Gorlaeus Laboratories of the Leiden Academic Centre for Drug Research
in accordance with the National Laws and the Directive 2010/63/EU of
the European Parliament. Animal studies are reported in compliance
with the ARRIVE guidelines.
ApoE knockout mice were originally obtained from The Jackson
Laboratory (The Jackson Laboratory, Bar Harbor, ME, USA) and sub-
sequently bred in house to expand the colony. Twelve week-old male
apoE knockout mice weighing on average 30.8 ± 0.5 g were chal-
lenged with a Western-type diet (0.25% cholesterol and 15% cocoa
butter, SDS, Sussex, UK) for 6 weeks to induce atherosclerotic lesion
development. During this period, the mice received 3 intraperitoneal
injections with SGC707 (10mg kg−1; N=12) or a similar amount of
solvent control (10 μl DMSO; N=12) per week. Mice were randomly
distributed over the two treatment groups. Body weight was monitored
twice weekly. Over the course of the study, 3 control mice developed
severe skin wounds, which led to elimination of these mice from the
study. After the 6-week intervention period, the remaining 21 mice
(SGC707 group: N=12; controls group: N=9) were bled in EDTA-
coated vials via tail incision for plasma lipid and hematological analysis
and anaesthetized by subcutaneous injection with a mix of 70mg kg−1
body weight xylazine, 1.8 mg kg−1 bodyweight atropine and
350mg kg−1 body weight ketamine. Animals were subsequently killed
by cervical dislocation. The arterial tree was perfused in situ with PBS
(100mmHg) for 10min via a cannula in the left ventricular apex. The
heart plus aortic root, liver, kidneys and gonadal white adipose tissue
were excised and stored in 3.7% neutral-buffered formalin (Formal-fixx;
Shandon Scientific Ltd., Runcorn, UK) for 24 h or stored at −20° until
further use.
2.2. Tissue lipid extraction and quantification
Triglycerides were extracted from liver and white adipose tissue
using Nonidet™ P 40 Substitute (Sigma-Aldrich Corp.). In brief, ap-
proximately 50mg of tissue was homogenized with 500 μl of Nonidet™
P 40 Substitute, heated until 90 °C and chilled on ice. The heating and
cooling procedure was repeated once more to solubilize all triglycerides
All insoluble material was removed by centrifuging at 13148× g. The
concentration of triglycerides was determined by the use of an enzy-
matic colorimetric assay. Cholesterol was extracted from liver tissue
using the Folch extraction method [12]. The concentration of free
cholesterol and cholesteryl esters in livers was determined by the use of
enzymatic colorimetric assays as described by Out et al. [13]. The
concentration of triglycerides, free cholesterol and cholesteryl esters
was corrected for the total protein concentration, determined using a
Pierce™ BCA Protein Assay Kit (ThermoFisher Diagnostics, Waltham,
MA, USA).
2.3. Plasma measurements
Concentrations of total cholesterol and triglycerides in plasma spe-
cimens were determined using enzymatic colorimetric assays (Roche
Diagnostics). The distribution over the different lipoproteins was ana-
lyzed by fractionation of 30 μl of plasma of each mouse using a
Superose 6 column (3.2× 300mm, Smart-system, Pharmacia). Plasma
alanine aminotransferase (ALT) levels were measured using Reflotron
test strips (Roche Diagnostics) according to the suppliers instructions at
the Gaubius building of TNO (Leiden, The Netherlands).
2.4. Hematological analysis
Total leukocyte numbers in whole blood samples with EDTA an-
ticoagulant obtained at sacrifice were routinely measured using an
automated Sysmex XT-2000iV Veterinary Hematology analyzer
(Sysmex Corporation). Verification of effects on specified white blood
cell subclasses was performed using fluorescence activated cell sorting
(FACS analysis) by staining cells with appropriate antibodies (CD11b,
Ly6G, CD4, CD8, CD19, CD86, CD62L, all obtained from eBioscience,
Belgium). For this purpose, blood was lysed using 0.83% NH4CL in
0.01M Tris/HCL pH 7.2. Subsequently, 300.000 cells were stained with
the indicated antibodies. FACS analysis was performed on the
FACSCalibur II (Becton Dickinson, Mountain View, CA). Identification
of specific leukocyte subsets was primarily based upon the indicated
fluorescent antibody signals, but was further validated by checking the
size and granularity of the tagged cells in the forward/side scatter plots.
Data were analyzed using FlowJo software. Peritoneal leukocytes were
obtained by lavaging the peritoneal cavity of the mice with 10ml of ice-
cold PBS. The percentage of foam cells in the total leukocyte population
was analyzed as described previously [14]. More specifically, peritoneal
cells displaying a high fluorescent signal in both forward-scattered light
(FSC) and side-scattered light (SSC) channels of the Sysmex apparatus
were labeled macrophage foam cells.
2.5. Histological analysis
Serial sections (10 μm) of the aortic root were cut using a Leica
CM3050S cryostat. The atherosclerotic lesion areas in Oil red O-stained
cryostat sections of the aortic root were quantified, in a blinded
manner, using the Leica image analysis system, consisting of a Leica
DMRE microscope coupled to a video camera and Leica Qwin Imaging
software (Leica Ltd., Cambridge, UK). Mean lesion area (in μm2) was
calculated from 5 consecutive sections of the aortic root, starting at the
appearance of the tricuspid valves. Cryosections of the liver (7 μm)
were generated and evaluated for the presence of neutral lipid using Oil
red O staining (Sigma-Aldrich, Zwijndrecht, The Netherlands). Paraffin
embedded liver and white adipose tissue was cut serially using a
RM2235 rotary microtome (Leica Ltd., Cambridge, UK) at intervals of
6 μm. The sections were subsequently routinely stained with hema-
toxilin (Sigma-Aldrich, Zwijndrecht, The Netherlands) and eosin
(Merck, Darmstadt, Germany). Liver paraffin sections were subjected to
Masson's Trichrome staining (Sigma-Aldrich, Zwijndrecht, The
Netherlands) to visualize collagen deposits (blue colour).
Representative images were obtained using the Leica image analysis
system. The number of adipocytes in white adipose tissue was manually
quantified within fixed areas (N=3 per group).
2.6. Analysis of gene expression by real-time quantitative PCR
Quantitative gene expression analysis was performed as described
[15]. Total RNA was isolated according to Chomczynski and Sacchi
[16] and reverse transcribed using RevertAid™ reverse transcriptase.
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Gene expression analysis was performed using real-time SYBR Green
technology (Eurogentec). Primer sequences are available on request.
Beta-actin, ribosomal protein L27, peptidylprolyl isomerase A, glycer-
aldehyde 3-phosphate dehydrogenase, and acidic ribosomal phospho-
protein P0 were used as the standard reference genes. Genes were
considered as being not expressed when they exhibited a Ct value
of> 35.
2.7. Microarray-based analysis of macrophage PRMT3 expression under
basal and atherogenic conditions
To generate bone marrow-derived macrophages, bone marrow cells
were isolated from femurs of C57BL/6 mice and cultured for 7 days in
complete RPMI medium supplemented with 20% FCS and 30% L929
cell-conditioned medium as a source of macrophage colony-stimulating
factor. After harvesting, cells were cultured overnight in DMEM con-
taining 10% FCS. Subsequently, cells were exposed to DMEM con-
taining 0.2% BSA with or without addition of foam cell inducing oxi-
dized LDL (oxLDL; 20 ng/ml) for 48 h. A RNAeasy mini kit (Qiagen,
Chatsworth, CA) was used to isolate total RNA (N=3 per group). After
checking the concentration and integrity of the RNA and an amplifi-
cation step (Ambion, #IL1791), the MouseWG-6 v2.0 microarray was
performed according to manufacturer's specifications (Illumina, San
Diego, CA). Probe ID 1990152 represented PRMT3. A relative expres-
sion level of> 80 arbitrary units was necessary for a transcript to be
considered as reliably detected.
2.8. Statistical analysis
Data are presented as means± SEM or means plus individual data
points. Statistical analysis was performed using Graphpad Instat soft-
ware (San Diego, USA, http://www.graphpad.com). Normality testing
of the experimental groups was performed using the method
Kolmogorov and Smirnov (Graphpad Instat). The significance of dif-
ferences was calculated using a two-tailed Student's t-test or two way
analysis of variance (ANOVA) with Bonferroni post-test where appro-
priate. Probability values< 0.05 were considered significant.
3. Results
3.1. Chronic PRMT3 inhibition reduces hepatic steatosis in apoE knockout
mice
Western-type diet-fed apoE× LXRalpha double knockout mice dis-
play whole body cholesterol accumulation and an increased athero-
sclerosis susceptibility as compared to apoE single knockout mice [17],
suggesting an important physiological role for endogenous LXR acti-
vation in apoE knockout mice during Western-type diet feeding.
SGC707 is an allosteric inhibitor of PRMT3 that does not impact the
activity for 31 other methyltransferases and>250 non-epigenetic tar-
gets [18]. To establish that PRMT3 inhibition can diminish the Western-
type diet-induced (LXR-driven) hepatic steatosis development, we in-
vestigated liver morphology in atherogenic diet-fed apoE knockout
mice after 6 weeks of parallel treatment with SGC707. Absolute liver
weight of SGC707-treated animals was significantly lower than in sol-
vent control-treated mice (−13%; P < 0.05; Fig. 1A). However, after
correcting the liver weight for total body weight the significance be-
tween the two groups was lost (5.4 ± 0.2% for SGC707-treated mice
versus 5.6 ± 0.3% for controls, respectively; P > 0.05). As can be
appreciated from the representative pictures in Fig. 1B, control-treated
mice apoE knockout mice developed fatty livers. More specifically,
significant macrovesicular steatosis was visible in hematoxylin/eosin-
stained liver paraffin sections from control-treated mice (Fig. 1B;
middle panels). Oil red O staining of cryosections validated the pre-
sence of large neutral lipid deposits (Fig. 1B; right panels). In ac-
cordance with the notion that mice only suffered from early stage fatty
liver disease (simple steatosis), we did not observe the hepatocellular
ballooning or intralobular inflammation phenotypes typically seen with
non-alcoholic steatohepatitis [3,19]. All liver sections stained with
Masson's Trichrome were negative for collagen (Fig. 1B; left panels),
which highlights the absence of non-alcoholic steatohepatitis-asso-
ciated fibrosis. Importantly, as also evident from Fig. 1B, mice chroni-
cally treated with SGC707 had developed less severe hepatic steatosis.
In contrast to the macrovesicular disease phenotype of control-treated
mice, SGC707-treated animals rather suffered from microvesicular
steatosis. As a result, only a limited amount of neutral lipid stores could
be found in Oil red O-stained liver sections of SGC707-treated mice.
Plasma levels of the hepatotoxicity marker alanine aminotransferase
(ALT) tended to be lower after SGC707 treatment (−27%; P=0.09;
Fig. 1C). Previous studies by Craig et al. have shown that changes in
absolute kidney weight reliably predict the occurrence of kidney toxi-
city [20]. Absolute kidney weights were not significantly different in
SGC707-treated mice (248 ± 9mg) as compared to control-treated
mice (270 ± 16mg). It can therefore be suggested that the observed
decrease in hepatic steatosis extent was not secondary to a (systemic)
toxic effect of SGC707 treatment. Chronic SGC707 exposure was also
not associated with the induction of liver inflammation. As such, he-
patic gene expression levels of the inflammatory cytokines monocyte
chemoattractant protein 1 (MCP1) and tumor necrosis factor alpha
(TNFα) and the macrophage marker CD68 were not different between
SGC707-treated and control mice (Fig. 1D). Quantification of the dif-
ferent major lipid species showed that livers of SGC707-treated mice
contained markedly less triglycerides (−51%; P < 0.05) as compared
to control mice (Fig. 1E). Hepatic free cholesterol (Fig. 1E) and cho-
lesteryl esters (Fig. 1E) levels were not different between both groups,
suggesting that the reduction in hepatic neutral lipid accumulation was
driven by a decrease in liver triglycerides.
3.2. Chronic PRMT3 inhibition does not impact the lipoprotein profile in
apoE knockout mice
In line with our previously published data in the short-term model
for murine hepatic steatosis [10], the changes in liver lipid status were
not paralleled by a change in plasma lipid levels. SGC707-treated mice
had similar plasma triglyceride (Fig. 2A) and total cholesterol (Fig. 2B)
levels. The distribution of the plasma cholesterol over the lipoprotein
fractions was also not markedly different in the two groups of mice
(Fig. 2C).
3.3. Chronic PRMT3 inhibition does not change the immune status of apoE
knockout mice
Protein arginine methyltransferase 1 (PRMT1), a family member of
PRMT3, modulates immune cell activation [21,22]. Although an im-
mune function has not yet been described for PRMT3, we determined
circulating leukocyte numbers and measured their activation status to
exclude that a cholesterol-independent immune modulatory effect of
PRMT3 is relevant in context of the development of atherosclerotic
lesions. Total circulating leukocytes were similar in both the SGC707-
treated group and the control group (Fig. 3A). Within the blood leu-
kocyte populations, a minor increase in the relative fraction of CD4+ T-
cells was detected in the mice treated with the PRMT3 inhibitor as
compared to controls (P < 0.05; Fig. 3B). It is generally assumed that
the activation and differentiation state of T-cells in atherosclerosis is
more important than their quantity [23,24]. Importantly, the distribu-
tion of CD4+ T-cells over the naïve, effector and memory effector
subsets was similar between both groups of mice (Fig. 3C).
3.4. Chronic PRMT3 inhibition does not change the foam cell extent or
atherosclerosis susceptibility in apoE knockout mice
Given that the SGC707 treatment did not impact on hepatic
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cholesterol levels, we verified that macrophage cholesterol metabolism
was also not changed in response to chronic PRMT3 inhibition. Notably,
as can be appreciated from our microarray findings displayed in
Supplemental Fig. 1, PRMT3 expression can be reliably detected in
bone marrow-derived macrophages already under control culture con-
ditions and PRMT3 levels actually increase under pro-atherogenic
conditions, i.e. during oxLDL-induced foam cell formation. However,
the percentage of macrophage foam cells in the peritoneal cavity was
similar after treatment of Western-type diet-fed apoE knockout mice
with SGC707 (Fig. 4A). This latter finding provides support for our
notion that the beneficial effect of LXR in the protection against foam
cell formation was not disrupted by the SGC707-mediated inhibition of
PRMT3 activity. To validate that the similar extent of foam cell for-
mation also translated into an unchanged atherosclerosis susceptibility,
we measured the atherosclerosis extent in the aortic root. Solvent
control-treated apoE knockout mice had developed initial athero-
sclerotic lesions with an average lesion area of 173 ± 22 ∗ 103 μm2
after 6 weeks on the Western-type diet. In concordance with the un-
changed plasma cholesterol, circulating leukocytes and foam cell
numbers, atherosclerotic lesions in the aortic root of SGC707-treated
mice stained with Oil red O for neutral lipids looked similar, as can be
appreciated from Fig. 4B. Quantification showed that the Oil red O-
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Fig. 1. Reduced accumulation of triglycerides in the liver in SGC707-treated apoE knockout mice. A) SGC707-treated mice showed a lower liver weight as compared
to control mice. B) Representative micrographs of livers stained with Masson's Trichrome (MT) for collagen, hematoxylin and eosin (H&E) and Oil red O (ORO) for
neutral lipids. C) Plasma alanine aminotransferase levels were not different. C) The change in steatosis extent was not accompanied by a change in the relative mRNA
expression levels of the inflammation markers monocyte chemoattractant protein 1 (MCP1), macrophage marker CD68 and tumor necrosis factor alpha (TNFα). D)
Liver triglycerides, but not free cholesterol and cholesteryl esters, were lower in SGC707-treated mice as compared to control mice. Black bars: SGC707 treated mice;
N=12. White bars: control treated mice; N=9. Graphs represent means ± SEM. * P < 0.05. (For interpretation of the references to colour in this figure legend,
the reader is referred to the web version of this article.)
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Fig. 2. SGC707 treatment did not affect
plasma lipids in apoE knockout mice. A)
Plasma triglyceride (TG) and B) total cho-
lesterol (TC) levels were not different in
SGC707-treated mice and the control
group. C) The distribution of cholesterol
over the different lipoprotein fractions in
plasma, including very-low-density lipo-
protein (VLDL), low-density lipoprotein
(LDL) and high-density lipoprotein (HDL)
was similar in both groups (N=3 per
group). Black bars: SGC707-treated mice;
N= 12. White bars: control treated mice;
N= 9. Graphs represent means ± SEM.
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positive lesion area was indeed not different in SGC707-treated mice as
compared to controls (146 ± 17 ∗ 103 μm2; Fig. 4C). Relative expres-
sion levels of the macrophage marker CD68 were determined in the
aortic arch as measure for initial atherosclerotic lesion development in
a second location. The results from the aortic root showing a null effect
of SGC707 treatment on atherosclerosis outcome were supported by the
similar gene expression levels of CD68 in the aortic arch of the two
groups of mice (Fig. 4D). Aortic PRMT3 gene expression levels were
measured to exclude that the null effect on atherosclerosis after SGC707
treatment was due to the fact that PRMT3 was not present locally in the
diseased vessel wall. In control mice, relative mRNA expression levels
of PRMT3 within the aortic arch were about half of those found in the
liver (0.0015 ± 0.0005 for aorta and 0.0034 ± 0.0002 for liver, re-
spectively). PRMT3 mRNA expression levels in aortic and liver speci-
mens of SGC707-treated mice were essentially the same as those in
control mice (0.0014 ± 0.0003 for aorta and 0.0037 ± 0.0002 for
liver). This latter finding highlights that chronic SGC707 treatment was
not associated with a compensatory feedback on the rate of PRMT3
gene transcription.
3.5. Chronic PRMT3 inhibition reduces weight gain in apoE knockout mice
Notably, we observed a 94% reduced (P < 0.05) body weight gain
upon Western-type diet feeding in the mice treated with SGC707 as
compared to control mice (Fig. 5A and B). Adipocytes in gonadal white
adipose tissue of SGC707-treated mice appeared slightly smaller during
tissue histological observation (Fig. 5C). In line with an anticipated
lower adipocyte volume, the number of adipocytes per quantified go-
nadal white adipose area was higher in SGC707-treated mice (93 ± 4
for SGC707-treated mice versus 76 ± 7 for controls; P < 0.05).
Browning was not visible in any of the gonadal white adipose tissue
sections. In accordance, gene expression of the classical brown adipose
tissue marker uncoupling protein 1 (UCP1) could not be measured in
~50% of the white adipose tissue samples (independent of the treat-
ment) and was equally low in the two groups of samples where UCP1
levels could be reliably detected (data not shown). In contrast, UCP1
mRNA expression levels were increased by 17-fold (P < 0.05) in sub-
cutaneous white adipose tissue upon SGC707 treatment (Fig. 5D).
Histological analysis of the subcutaneous white adipose tissue depots
showed significant browning in the SCG707-treated mice. As evident
from Fig. 5C, adipocytes in subcutaneous white adipose tissue of
SCG707-treated mice generally appeared to be smaller. Furthermore,
the appearance of adipocytes in several parts within the subcutaneous
white fat depot was more reminiscent of brown adipocytes.
Previous studies in cultured adipocytes and wild-type and LXR
knockout mice have suggested that LXR not only controls the tran-
scription of the lipogenic transcription factor SREBP-1c in hepatocytes
but also in adipocytes/adipose tissue [25,26]. As can be appreciated
from the gonadal white adipose tissue gene expression profile in
Fig. 5E, levels of SREBP-1c and the lipogenesis genes FAS, ACC1, and
SCD1 were not significantly altered by SGC707 treatment. In contrast,
SGC707 treatment was associated with a significant decrease (−48%;
P < 0.05) in the mRNA expression levels of lipoprotein lipase (LPL)
that, in adipocytes, facilitates the local catabolism of lipoprotein-
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Fig. 3. No functional changes in circulating leukocytes in SGC707-treated apoE knockout mice. A) Total circulating leukocyte numbers were not different between
the two experimental groups. B) The distribution of the leukocytes over the different cell subsets showed only a minor increase in CD4+ T-cells in SGC707-treated
mice as compared to control treated mice. C) The activity of the CD4+ T-cells was not affected by SGC707 treatment. Black bars: SGC707 treated mice; N= 12.
White bars: control treated mice; N= 9. Graphs represent means ± SEM. * P < 0.05.
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Fig. 4. SGC707 treatment did not affect foam cell formation or atherosclerosis susceptibility in apoE knockout mice. A) The quantity of foam cells as percentage of
total peritoneal leukocytes was not different in the SGC707-treated mice and control mice. B) Representative micrographs of the aortic root stained with Oil red O for
neutral lipids (red) 5× objective. C) The aortic atherosclerotic lesion area did not differ significantly between SGC707-treated mice (black circles) and the control
group (white circles). D) Relative gene expression of CD68 in the aortic arch was similar in both groups. Black bars: SGC707-treated mice; N= 12. White bars: control
treated mice; N=9. Graphs represent means ± SEM. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of
this article.)
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associated triglycerides for subsequent cellular uptake of the liberated
fatty acids. Importantly, the decrease in LPL expression was paralleled
by a clear trend towards a decrease (−52%; P= 0.07) in the relative
expression level of the scavenger receptor CD36 that mediates the ac-
tual uptake of lipoprotein-derived fatty acids.
4. Discussion
Previously published in vitro and in vivo studies have proposed that
PRMT3 is a coactivator for LXR that modulates LXR's lipogenic but not
its function in cholesterol metabolism [9,10]. Here we show that
chronic treatment of hyperlipidemic apoE knockout mice with the
PRMT3 inhibitor SGC707 reduced the hepatic steatosis extent, while
atherosclerotic lesion development was not negatively affected. This
finding provides further evidence that through PRMT3 inhibition the
LXR-driven (pathological) effects on fatty acid and cholesterol meta-
bolism can be uncoupled.
As we expected based on previously published work [9,10] and the
observation that plasma cholesterol levels, blood leukocyte numbers
and the extent of in vivo foam cell formation are not changed by
SGC707 treatment, atherosclerotic lesion susceptibility was not mod-
ified by pharmacological inhibition of PRMT3 activity. Interestingly,
PRMT3 has recently emerged as a putative novel target in the context of
atherosclerosis and cardiovascular disease in humans. Chen et al. de-
tected a 2-fold higher mRNA expression of PRMT3 in myocardial tissue
from patients suffering from cardiovascular disease as compared to that
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Fig. 5. SGC707 treatment attenuated body weight gain of apoE knockout mice. A) SGC707-treated mice (black circles) gained less weight during 6weeks of Western-
type diet feeding as compared to control mice (white circles). Data are expressed as fold change versus the starting weight. B) Absolute body weight gain was
significantly reduced in SGC707-treated mice. C) Representative micrographs of white adipose tissue of both groups. D) White adipose tissue triglyceride (TG) levels,
corrected for the amount of protein, tended to be lower in SGC707-treated mice as compared to control mice. E) SGC707-treated mice tended to have smaller
adipocytes, as the number of cells per quantified area was slightly increased (N=3 per group). F) Relative expression levels of lipolysis and fatty acid uptake but not
lipogenesis genes were lower in SGC707-treated mice. Black bars: SGC707-treated mice; N=12. White bars: control treated mice; N= 9. Graphs represent
means ± SEM. * P < 0.05.
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from subjects without atherosclerotic vessel disease [27]. In addition,
human association studies by Shendre et al. have linked variation in the
PRMT3 gene to a change in common carotid intima-media thickness
(cCIMT), a measure of subclinical atherosclerosis [28]. Shendre et al.
furthermore showed that the local European ancestry region in the
PRMT3 gene is associated with a ~2 times higher stroke risk in African
Americans [28]. This observational data suggest a role for PRMT3 in
atherosclerosis. It is noteworthy that besides its proposed function as
nuclear cofactor, PRMT3 belongs to the family of protein arginine N-
methyltransferase enzymes that transfer methyl groups to the arginine
residues of histones and other proteins to produce asymmetric di-
methylarginine (ADMA) and, to a minor extent, symmetric dimethy-
larginine (SDMA). ADMA is a potent inhibitor of the formation of the
anti-atherogenic agent nitric oxide [29]. Accordingly, ADMA increases
atherosclerosis susceptibility in wild-type and apoE knockout mice
[30,31]. In support of a negative impact of ADMA on atherosclerosis
outcome in humans, high plasma ADMA levels serve as an independent
predictor of high IMT levels in a variety of clinical settings [32,33].
Moreover, subjects in the highest quartile for plasma ADMA levels
display a 3.9-fold increased risk for acute coronary events [34]. From
our current study it can be concluded that complete inhibition of
PRMT3 activity does not affect ADMA functionality in the cardiovas-
cular context as we did not measure an effect on atherosclerosis out-
come. It should however, be taken into account that we administered a
dose of the PRMT3 inhibitor at which we aimed to be able to measure
an effect on hepatic triglyceride accumulation. Although the hepatic
steatosis extent was effectively lowered, it is currently unclear whether
the dose of 10mg kg−1 SGC707 is also sufficiently high to interfere
with the ADMA/nitric oxide system. We did not detect an effect on
systemic/plasma ADMA levels (data not shown). However, this does not
necessarily exclude a potential (undetermined) impact of the chronic
SGC707 treatment at an individual cellular level, i.e. in the aortic vessel
wall. Further dedicated research, i.e. on vessel wall reactivity, may
provide better insight in the potential of SGC707 to functionally mod-
ulate the body's ADMA/nitric oxide status and uncover the relevance in
the cardiovascular disease setting, especially also since redundancy
between the different PRMT family members has been suggested [35].
An interesting observation during our studies was that SGC707-
treated mice, in marked contrast to control-treated mice, did not gain
additional weight during the six week Western-type diet feeding period.
Brown adipose tissue has emerged as a potential target to combat
obesity due to its ability to burn fatty acids to produce heat, thereby
eliminating storage of fat in white adipose tissue [36,37]. Since we did
not primarily intend to investigate the effect of chronic SGC707 ex-
posure on obesity development, a full metabolic profiling of the mice is
unfortunately lacking. As such, we do not known the exact food intake
nor the extent of heat produced by brown adipose tissue in the two
groups of mice. Previous studies by Chen et al. have shown that ex-
posure of C3H10T1/2 murine mesenchymal progenitor cells to the
PRMT3 inhibitor compound 14u does not affect the ability of these cells
to differentiate into brown adipocytes in vitro [38]. However, we ob-
served a striking increase in browning of the subcutaneous white adi-
pose tissue depot, which was paralleled by a marked increase in white
adipose tissue UCP1 transcript levels. The decreased body weight gain
can thus theoretically be the result of a higher heat production instead
of fatty acid storage in white adipose tissue. However, dedicated in vivo
studies are clearly warranted to decipher the exact function of PRMT3
in obesity development. The lower final body weight in SGC707-treated
mice was also paralleled by a small change in the relative number of
adipocytes in gonadal white adipose tissue. Strikingly, the change in
gonadal white adipose tissue phenotype did not coincide with a de-
crease in the expression levels of the lipogenic genes SREBP-1c, FAS,
ACC1, and SCD1, as we would have expected from our previous find-
ings regarding PRMT3 functionality in liver [10]. The mRNA expression
levels of LPL and CD36 were – however – lowered in gonadal white
adipose tissue after SGC707 treatment. Adipose tissue-specific LPL
deficiency does not change the obesogenic potential of mice [39]. In
contrast, CD36 total body knockout mice as compared to their wild-type
counterparts exhibit reduced adiposity in response to a high fat diet
challenge, which appears to be driven by a reduction in the adipocyte
uptake of lipoprotein-derived fatty acids and the associated reduction in
white adipose tissue weight [40,41]. From these combined findings, it
can be hypothesized that (1) the lipogenesis regulatory function of
PRMT3 is perhaps restricted to hepatocytes and (2) that SGC707
treatment may actually decrease obesity development by lowering
adipose tissue fatty acid uptake and switching white adipocytes to a
more brown phenotype.
In conclusion, we have shown that treatment with the PRMT3 in-
hibitor SGC707 reduces hepatic steatosis without a negative impact on
atherosclerosis susceptibility in hyperlipidemic mice. As such, our
findings highlight that PRMT3 inhibition may constitute a novel ther-
apeutic approach to limit the development of fatty liver disease in
humans. Furthermore, the unanticipated decrease in body weight gain
and changes in white adipose tissue associated with chronic SGC707
treatment imply a potential novel role for PRMT3 in white adipose
tissue homeostasis and adipocyte function, which has to be validated in
further research.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.bbadis.2019.02.012.
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